UCI-created stem cell treatment passes safety phase of clinical trial
Doctors with the Balgrist University Hospital in Zurich report that the surgery, immunosuppression and cell transplants have been well tolerated.
Doctors with the Balgrist University Hospital in Zurich have reported that a stem cell treatment developed in a collaboration among UCI’s Aileen Anderson and Brian Cummings (pictured), the campus’s Sue & Bill Gross Stem Cell Research Center and StemCells Inc. has passed the first planned interim safety review of the Phase I/II spinal cord injury clinical trial, which indicates that the surgery, immunosuppression and cell transplants have been well tolerated. The StemCells Inc.-sponsored trial is the only ongoing clinical study of neural stem cell transplantation in spinal cord injury. Enrollment is now open to patients in Europe, the U.S. and Canada with “incomplete” spinal cord injury.